PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers. We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document. We look forward to being of service to you. If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf. Phone: +44 (0)1300 321501 or Email: reportstore@bioportfolio.com 2

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels of inattention, impulsivity, and hyperactivity, either alone or in combination that have a significant social impact through disruptions at school, work, home, and in relationships. The majority of children with the disorder will continue to experience symptoms into adolescence. 30-50% of children diagnosed with ADHD continue to have problems into adulthood resulting in 2-5% of adults having ADHD. Growth is expected in the global ADHD marketplace, despite the market being widely genericized. This will be driven largely by the anticipated launch of assets from the heavily populated ADHD pipeline, as these products offer clinical advantages that will drive strong uptake. Furthermore, the number of drug-treated patients will increase over the forecast period, driven by increased treatment rates throughout the 7MM, particularly in the adult age group. Highlights Key Questions Answered - The ADHD market has been dominated by stimulant therapy, with only three approved non-stimulant drugs approved that cannot compete with stimulant drugs in terms of efficacy. Due to lack of evidence for long-term safe use of stimulants, non-stimulants are becoming increasingly popular in the 7MM. Both stimulant and nonstimulant therapies are anticipated to reach the market within the forecast period. How will these change the market overall during the forecast period? Will stimulants maintain market dominance in 2024? - The current late stage ADHD pipeline is heavily populated, drugs designed to satisfy what GlobalData has identified as unmet needs. Which of these will have the biggest impact on the market? What strategies are developers undertaking to penetrate this crowded market? - ADHD is becoming increasingly recognized, particularly n the adult population, leading to increase number in treated patients across the 7MM. How will these changes impact the growth of the future market? Key Findings - The main driver of growth in the ADHD market will be the increase in the number of drug-treated patients, driven by an increase in treatment rates expected to 2024, particularly in the adult age group. - Lack of awareness and recognition of ADHD leads to misdiagnosis; this has acted as a barrier to appropriate treatment for ADHD. - The arrival of new therapies across the 7MM will increase treatment rates and provide alternative options for 3

many patients, particularly those who have difficulty or who dislike swallowing pills and those who choose nonstimulant therapy. - One of the key unmet needs in the ADHD market of additional treatment options will be somewhat satisfied by the emerging pipeline assets during the forecast. Despite the increasingly competitive nature of the ADHD market, lucrative opportunities remain for products that target unmet needs. In addition, providing clinically relevant, head-to-head comparisons is an important consideration for companies developing drugs to treat these patients. Scope - Overview of ADHD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines. - Annualized ADHD market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024. - Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the ADHD therapeutics market. - Pipeline analysis: focus on 13 late-stage pipeline ADHD drugs discussing emerging trends as well as an overview of earlier phase drugs. - Analysis of the current and future market competition in the global ADHD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. Reasons to buy The report will enable you to - - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list. - Develop business strategies by understanding the trends shaping and driving the global ADHD therapeutics market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global ADHD therapeutics market in future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Track drug sales in the global ADHD therapeutics market from 2014-2024. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. Additional Details Publisher : Global Data 4

Reference : GDHC125PIDR Number of Pages : 369 Report Format : PDF Publisher Information : 5

Table Of Contents for PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 1 Table of Contents1 Table of Contents 111.1 List of Tables 171.2 List of Figures 242 Introduction 262.1 Catalyst 262.2 Related Reports 272.3 Upcoming Related Reports 273 Disease Overview 283.1 Etiology and Pathophysiology 283.1.1 Etiology 283.1.2 Pathophysiology 313.2 Classification 323.2.1 Predominantly Inattentive Type 333.2.2 Predominantly Hyperactive-Impulsive Type 333.2.3 Combined Type 343.2.4 Other Specified ADHD Type 343.2.5 Unspecified Type 343.2.6 Severity 343.3 Symptoms 353.4 Prognosis 364 Epidemiology 384.1 Disease Background 384.2 Risk Factors and Comorbidities 394.3 Global Trends 414.3.1 US 414.3.2 5EU 414.3.3 Japan 434.4 Forecast Methodology 434.4.1 Sources Used Tables 444.4.2 Forecast assumptions and methods 484.4.3 Sources Not Used 614.5 Epidemiological Forecast for ADHD (2014-2024) 624.5.1 Diagnosed Prevalent Cases of ADHD 624.5.2 Age-Specific Diagnosed Prevalent Cases of ADHD 644.5.3 Sex-Specific Diagnosed Prevalent Cases of ADHD 664.5.4 Age-Standardized Prevalence of ADHD 684.5.5 Diagnosed Prevalent Cases of ADHD by Subtype 694.6 Discussion 734.6.1 Epidemiological Forecast Insight 734.6.2 Limitations of the Analysis 754.6.3 Strengths of the Analysis 765 Disease Management 775.1 Diagnosis and Treatment Overview 775.1.1 Diagnosis 775.1.2 Treatment Guidelines and Leading Prescribed Drugs 795.1.3 Clinical Practice 845.2 US 855.3 5EU 895.4 Japan 956 Competitive Assessment 996.1 Overview 996.2 Product Profiles - Amphetamine (Stimulant) 1026.2.1 Dextroamphetamine 1036.2.2 Desoxyn (methamphetamine) 1086.2.3 Adderall XR (Mixed amphetamine Salts) 1116.2.4 Vyvanse (lisdexamphetamine dimesylate) 1166.2.5 Dyanavel XR (Liquid Amphetamine XR) 1226.2.6 Adzenys XR-ODT (Amphetamine Extended Release-Orally Disintegrating Tablet) 1266.3 Product Profiles - Methylphenidate (Stimulant) 1306.3.1 Ritalin LA 1316.3.2 Concerta 1366.3.3 Medikinet XL 1426.3.4 Metadate CD 1466.3.5 Methylin 1516.3.6 Focalin 1546.3.7 Daytrana 1586.3.8 Quillivant XR/Quillichew 1636.3.9 Aptensio XR 1676.4 Product Profiles - Nonstimulants 1716.4.1 Strattera (Atomoxetine Hydrochloride) 1726.4.2 Intuniv (Guanfacine Hydrochloride) 1816.4.3 Kapvay (Clonidine) 1876.4.4 Other Therapeutic Classes 1917 Unmet Need and Opportunity Analysis 1937.1 Overview 1937.2 More Effective, Longer-Lasting, and/or Non-stimulant Treatment Options 1947.2.1 Unmet Need 1947.2.2 Gap Analysis 1967.2.3 Opportunity 1967.3 Clinically Relevant, Head-to-Head Comparisons 1977.3.1 Unmet Need 1977.3.2 Gap Analysis 1997.3.3 Opportunity 1997.4 Improved Diagnostic Tests 1997.4.1 Unmet Need 1997.4.2 Gap Analysis 2007.4.3 Opportunity 2007.5 Education and Recognition of ADHD 2007.5.1 Unmet Need 2007.5.2 Gap Analysis 2027.5.3 Opportunity 2027.6 Discontinuation and Long- Term Safety of Stimulants 2037.6.1 Unmet Need 2037.6.2 Gap Analysis 2047.6.3 Opportunity 2058 Pipeline Assessment 2068.1 Overview 2068.2 Clinical Trial Mapping 2068.2.1 Clinical Trials by Class 2068.3 Overview of Promising Drugs in Clinical Development 2088.4 Promising Amphetamine Drugs in Clinical Development 2118.4.1 NT-0201 (Liquid Amphetamine XR) 2118.4.2 SHP-465 (Triple-Bead Mixed Amphetamine Salts) 2158.4.3 HLD-100 (Dextroamphetamine MR) 2208.4.4 Amphetamine Transdermal System (Dextroamphetamine) 2258.5 Promising Methylphenidate Drugs in Clinical Development 2298.5.1 Cotempla XR-ODT (Extended-Release ODT Methylphenidate) 2298.5.2 Benjorna (Methylphenidate Hydrochloride MR) 2338.6 Promising Non-stimulant Drugs in Clinical Development 2388.6.1 SEP-225289 (Dasotraline) 2388.6.2 Centanafadine SR 2438.6.3 SPN-810 (Molindone Hydrochloride ER) 2478.6.4 SPN-812 (Viloxazine Hydrochloride) 2528.6.5 Metadoxine ER 2568.6.6 Eltoprazine 2628.6.7 CM-4612 2668.7 Other Drugs in Development 2709 Current and Future Players 2729.1 Overview 2729.2 Trends in Corporate Strategy 2759.3 Company Profiles 2769.3.1 Shire 2769.3.2 Novartis 2809.3.3 Janssen 2829.3.4 Eli Lilly 2849.3.5 Pfizer/Tris Pharma 2869.3.6 Highland Therapeutics 29010 Market Outlook 29310.1 Global Markets 29310.1.1 Forecast 29310.1.2 Drivers and Barriers - Global Issues 29910.2 US 30010.2.1 Forecast 30010.2.2 Key Events 30510.2.3 Drivers and Barriers 30610.3 5EU 30710.3.1 Forecast 30710.3.2 Key Events 31110.3.3 Drivers and Barriers 31110.4 Japan 31210.4.1 Forecast 31210.4.2 Key Events 31410.4.3 Driver and Barriers 31511 Appendix 31611.1 Bibliography 31611.2 Abbreviations 34311.3 Methodology 34911.4 Forecasting Methodology 34911.4.1 Diagnosed ADHD Patients 34911.4.2 Percent Drug-Treated Patients 35011.4.3 Launch and Patent Expiry Dates 35011.4.4 General Pricing Assumptions 35011.4.5 Individual Drug Assumptions 35111.4.6 Generic Erosion 36011.4.7 Pricing of Pipeline Agents 36011.5 Primary Research - KOLs Interviewed for This Report 36211.6 Primary Research - Prescriber Survey 36411.7 About the Authors 36511.7.1 Analyst 36511.7.2 Therapy Area Director 36511.7.3 Epidemiologists 36511.7.4 Managing Epidemiologists 36611.7.5 6

Global Director of Therapy Analysis and Epidemiology 36711.8 About GlobalData 36811.9 Disclaimer 368 7

List Of Tables in PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 1.1 List of Tables Table 1: Classification of ADHD According to the DSM-V and ICD-10-CM 33 Table 2: Symptoms of ADHD 36 Table 3: Prognosis and Risks Associated with ADHD 37 Table 4: Risk Factors and Comorbidities for ADHD 40 Table 5: 7MM, Sources of Epidemiological Data Used to Forecast Diagnosed Prevalent Cases of ADHD 44 Table 6: 7MM, Sources of Epidemiological Data Used to Forecast Diagnosed Prevalent Cases of ADHD by Subtype, Ages 3 17 Years 46 Table 7: 7MM, Sources of Epidemiological Data Used to Forecast Diagnosed Prevalent Cases of ADHD by Subtype, Ages 18 Years 47 Table 8: 7MM, Sources Not Used in Epidemiological Analysis of ADHD 61 Table 9: 7MM, Diagnosed Prevalent Cases of ADHD, Both Sexes, Ages 3 Years, Select Years, 2014-2024 63 Table 10: 7MM, Age-Specific Diagnosed Prevalent Cases of ADHD, Both Sexes, N (Row%), 2014 65 Table 11: 7MM, Sex-Specific Diagnosed Prevalent Cases of ADHD, Ages 3 Years, N (Row %), 2014 67 Table 12: 7MM, Diagnosed Prevalent Cases of ADHD, by Subtype, Ages 3-17 Years, Children and Adolescents, N (Row %), 2014 70 Table 13: 7MM, Diagnosed Prevalent Cases of ADHD, by Subtype, Ages 18 Years, Adults, N (Row %), 2014 72 Table 14: Rating Scales Used for ADHD 79 Table 15: Treatment Guidelines for Disease ADHD 81 Table 16: Most Prescribed Drugs for ADHD by Class in the Global Markets, 2014 83 Table 17: Country Profile - US 88 Table 18: Country Profile - 5EU 93 Table 19: Country Profile - Japan 98 Table 20: Leading Treatments for ADHD, 2015 101 Table 21: Product Profile - Dextroamphetamine 105 Table 22: Dextroamphetamine SWOT Analysis, 2015 107 Table 23: Global Sales Forecasts ($m) for Dextroamphetamine, 2014-2024 108 Table 24: Product Profile - Desoxyn 109 Table 25: Desoxyn SWOT Analysis, 2015 110 8

Table 26: Global Sales Forecasts ($m) for Desoxyn, 2014-2024 111 Table 27: Product Profile - Adderall XR 113 Table 28: Adderall XR SWOT Analysis, 2015 115 Table 29: Global Sales Forecasts ($m) for Adderall XR, 2014-2024 116 Table 30: Product Profile - Vyvanse 119 Table 31: Vyvanse SWOT Analysis, 2015 121 Table 32: Global Sales Forecasts ($m) for Vyvanse, 2014-2024 122 Table 33: Product Profile - Dyanavel XR 123 Table 34: Dyanavel SWOT Analysis, 2015 125 Table 35: Global Sales Forecasts ($m) for Dyanavel XR, 2014-2024 126 Table 36: Product Profile - Adzenys XR-ODT 128 Table 37: Adzenys XR-ODT SWOT Analysis, 2015 129 Table 38: Global Sales Forecasts ($m) for Adzenys XR-ODT, 2014-2024 130 Table 39: Product Profile - Ritalin LA 134 Table 40: Ritalin LA SWOT Analysis, 2015 135 Table 41: Global Sales Forecasts ($m) for Ritalin LA, 2014-2024 136 Table 42: Product Profile - Concerta 138 Table 43: Concerta SWOT Analysis, 2015 141 Table 44: Global Sales Forecasts ($m) for Concerta, 2014-2024 142 Table 45: Product Profile - Medikinet XL 143 Table 46: Medikinet SWOT Analysis, 2015 145 Table 47: Global Sales Forecasts ($m) for Medikinet XL, 2014-2024 146 Table 48: Product Profile - Metadate CD 148 Table 49: Incidence of TEAEs in a Pool of 3-4 Week Clinical Trials - Metadate CD 149 Table 50: Metadate CD SWOT Analysis, 2015 150 Table 51: Global Sales Forecasts ($m) for Metadate CD, 2014-2024 151 Table 52: Product Profile - Methylin 152 Table 53: Methylin SWOT Analysis, 2015 153 Table 54: Global Sales Forecasts ($m) for Methylin, 2014-2024 154 Table 55: Product Profile - Focalin 155 Table 56: TEAEs - Focalin 157 9

Table 57: TEAEs - Focalin XR 157 Table 58: Focalin SWOT Analysis, 2015 157 Table 59: Global Sales Forecasts ($m) for Focalin and Focalin XR, 2014-2024 158 Table 60: Product Profile - Daytrana 160 Table 61: Daytrana SWOT Analysis, 2015 162 Table 62: Global Sales Forecasts ($m) for Daytrana, 2014-2024 163 Table 63: Product Profile - Quillivant XR 164 Table 64: Quillichew Primary Efficacy Result 165 Table 65: Quillivant XR SWOT Analysis, 2015 166 Table 66: Global Sales Forecasts ($m) for Quillivant XR/Quillichew, 2014-2024 167 Table 67: Product Profile - Aptensio XR 168 Table 68: Summary of the Parallel Group Study - Aptensio XR 169 Table 69: Aptensio XR SWOT Analysis, 2015 170 Table 70: Global Sales Forecasts ($m) for Aptensio XR, 2014-2024 170 Table 71: Product Profile - Strattera 174 Table 72: Acute and Maintenance Efficacy Studies - Strattera 176 Table 73: Common TEAEs reported in acute trials in children and adolescents - Strattera 178 Table 74: Common TEAEs reported in acute trials in adults - Strattera 179 Table 75: Strattera SWOT Analysis, 2015 180 Table 76: Global Sales Forecasts ($m) for Strattera, 2014-2024 181 Table 77: Product Profile - Intuniv 183 Table 78: Fixed Dose Studies- Intuniv 184 Table 79: Intuniv SWOT Analysis, 2015 186 Table 80: Global Sales Forecasts ($m) for Intuniv, 2014-2024 187 Table 81: Product Profile - Kapvay 188 Table 82: Kapvay SWOT Analysis, 2015 190 Table 83: Global Sales Forecasts ($m) for Kapvay, 2014-2024 191 Table 84: Unmet Need and Opportunity in ADHD 194 Table 85: Drugs in Development, 2016 210 Table 86: Comparison of Therapeutic Classes in Development for ADHD, 2014-2024 210 Table 87: Product Profile - Liquid Amphetamine XR, NT-0201 212 10

Table 88: NT-0201 SWOT Analysis, 2015 214 Table 89: Global Sales Forecasts ($m) for NT-0201, 2014-2024 214 Table 90: Product Profile - Triple-Bead Mixed Amphetamine Salts (SHP-465) 216 Table 91: SHP-465 SWOT Analysis, 2015 219 Table 92: Global Sales Forecasts ($m) for SHP-465, 2014-2024 220 Table 93: Product Profile - HLD-100 221 Table 94: HLD-100 SWOT Analysis, 2015 224 Table 95: Global Sales Forecasts ($m) for HLD-100, 2014-2024 224 Table 96: Product Profile - Dextroamphetamine Transdermal Patch 226 Table 97: Dextroamphetamine Transdermal Patch SWOT Analysis, 2015 228 Table 98: Global Sales Forecasts ($m) for ATS, 2014-2024 229 Table 99: Product Profile - Cotempla XR-ODT 230 Table 100: Cotempla XR-ODT SWOT Analysis, 2015 232 Table 101: Global Sales Forecasts ($m) for Cotempla XR-ODT, 2014-2024 233 Table 102: Product Profile - Benjorna 234 Table 103: Benjorna SWOT Analysis, 2015 237 Table 104: Global Sales Forecasts ($m) for Benjorna, 2014-2024 238 Table 105: Product Profile - Dasotraline 239 Table 106: Dasotraline SWOT Analysis, 2015 242 Table 107: Global Sales Forecasts ($m) for dasotraline, 2014-2024 242 Table 108: Product Profile - Centanafadine SR 244 Table 109: Centanafadine SR SWOT Analysis, 2015 246 Table 110: Global Sales Forecasts ($m) for centanafadine SR, 2014-2024 247 Table 111: Product Profile - SPN-810 248 Table 112: SPN-810 SWOT Analysis, 2015 251 Table 113: Global Sales Forecasts ($m) for SPN-810, 2014-2024 252 Table 114: Product Profile - Viloxazine 253 Table 115: Viloxazine SWOT Analysis, 2015 255 Table 116: Global Sales Forecasts ($m) for Pipeline Viloxazine, 2014-2024 256 Table 117: Product Profile - Metadoxine ER 258 Table 118: Metadoxine ER SWOT Analysis, 2015 261 11

Table 119: Global Sales Forecasts ($m) for Metadoxine ER, 2014-2024 262 Table 120: Product Profile - Eltoprazine 263 Table 121: Eltoprazine SWOT Analysis, 2015 265 Table 122: Global Sales Forecasts ($m) for Eltoprazine, 2014-2024 265 Table 123: Product Profile - CM-4612 267 Table 124: CM-4612 SWOT Analysis, 2015 269 Table 125: Global Sales Forecasts ($m) for CM-4612, 2014-2024 270 Table 126: Drugs in Development, 2016 271 Table 127: Key Companies in the ADHD Market in the 7MM, 2014 273 Table 128: Shire s ADHD Portfolio Assessment, 2015 279 Table 129: Novartis ADHD Portfolio Assessment, 2015 281 Table 130: Janssen s ADHD Portfolio Assessment, 2015 283 Table 131: Eli Lilly s ADHD Portfolio Assessment, 2015 285 Table 132: Pfizer/Tris Pharma s ADHD Portfolio Assessment, 2015 288 Table 133: Highland Therapeutics ADHD Portfolio Assessment, 2016 291 Table 134: Global Sales Forecasts ($m) for ADHD, 2014-2024 295 Table 135: ADHD Market - Global Drivers and Barriers, 2014 2024 299 Table 136: Sales Forecasts ($m) for ADHD in the US, 2014-2024 302 Table 137: Key Events Impacting Sales for ADHD in the US, 2014-2024 305 Table 138: ADHD Market - Drivers and Barriers in the US, 2014 2024 306 Table 139: Sales Forecasts ($m) for ADHD in the 5EU, 2014-2024 309 Table 140: Key Events Impacting Sales for ADHD in the 5EU, 2014-2024 311 Table 141: ADHD Market - Drivers and Barriers in the 5EU, 2014 2024 311 Table 142: Sales Forecasts ($m) for ADHD in Japan, 2014-2024 313 Table 143: Key Events Impacting Sales for ADHD in Japan, 2014-2024 314 Table 144: ADHD Market - Drivers and Barriers in Japan, 2014 2024 315 Table 145: Key ADHD Launch Dates 350 Table 146: Key ADHD Patent Expiries 350 Table 147: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country, 2016 364 12

List Of Figures, Charts and Diagrams in PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 1.2 List of Figures Figure 1: 7MM, Diagnosed Prevalent Cases of ADHD, Both Sexes, Ages 3 Years, Selected Years, 2014-2024 64 Figure 2: 7MM, Age-Specific Diagnosed Prevalent Cases of ADHD, Both Sexes, 2014 66 Figure 3: 7MM, Sex-Specific Diagnosed Prevalent Cases of ADHD, Ages 3 Years, 2014 68 Figure 4: 7MM, Age-Standardized Diagnosed Prevalence of ADHD, Ages 3 Years, 2014 69 Figure 5: 7MM, Diagnosed Prevalent Cases of ADHD, by Subtype, Ages 3-17 Years, Children and Adolescents, N, 2014 71 Figure 6: 7MM, Diagnosed Prevalent Cases of ADHD, by Subtype, Ages 18 Years, Adults, N, 2014 73 Figure 7: Treatment Algorithm for ADHD in the 7MM 80 Figure 8: ADHD Therapeutics - Class of Therapy, 2016 207 Figure 9: ADHD - Phase II-III Pipeline, 2016 208 Figure 10: Competitive Assessment of Late-Stage Pipeline Agents in ADHD, 2014-2024 209 Figure 11: Clinical and Commercial Positioning of NT-0201 213 Figure 12: Clinical and Commercial Positioning of SHP-465 218 Figure 13: Clinical and Commercial Positioning of HLD-100 223 Figure 14: Clinical and Commercial Positioning of ATS 227 Figure 15: Clinical and Commercial Positioning of Cotempla XR-ODT 231 Figure 16: Clinical and Commercial Positioning of Benjorna 236 Figure 17: Clinical and Commercial Positioning of Dasotraline 241 Figure 18: Clinical and Commercial Positioning of Centanafadine SR 245 Figure 19: Clinical and Commercial Positioning of SPN-810 250 Figure 20: Clinical and Commercial Positioning of Viloxazine 254 Figure 21: Clinical and Commercial Positioning of Metadoxine ER 260 Figure 22: Clinical and Commercial Positioning of Eltoprazine 264 Figure 23: Clinical and Commercial Positioning of CM-4612 268 Figure 24: Global Sales of Branded Products for ADHD by Company, 2014-2024 274 Figure 25: Company Portfolio Gap Analysis in ADHD, 2014-2024 275 Figure 26: Shire SWOT Analysis in ADHD, 2014-2024 280 13

Figure 27: Novartis SWOT Analysis in ADHD, 2014-2024 282 Figure 28: Janssen SWOT in ADHD, 2014-2024 284 Figure 29: Eli Lilly SWOT Analysis in ADHD, 2014-2024 286 Figure 30: Pfizer/Tris Pharma SWOT Analysis in ADHD, 2014-2024 289 Figure 31: Highland Therapeutics SWOT Analysis in ADHD, 2014-2024 292 Figure 32: Global Sales for ADHD by Country, 2014 and 2024 297 Figure 33: Global Sales for ADHD by Drug Class, 2014 and 2024 298 Figure 34: Sales for ADHD by Drug Class in the US, 2014 and 2024 304 Figure 35: Sales for ADHD by Drug Class in the 5EU, 2014 and 2024 310 Figure 36: Sales for ADHD by Drug Class in Japan, 2014 and 2024 314 14

How to Buy... PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Option 1 - Online Go to our website and pay online with any major debit or credit card: Option 2 - Request a Proforma Invoice Fill in the details below, and either Scan this page and email it to us at reportstore@bioportfolio.com or Fax it to us at +44 (0)1305 791844.We will send you a Proforma Invoice and deliver your report on settlement. Your Name: Job Title: Your Email: Your Contact Phone: Company Name: Address: Post/Zip Code: Country: P.O. Number: Any Other Instructions: Pricing Options: (please tick one) $10995 Single User Price $21990 Site License Price $32985 Enterprise License Price Payment Options: (please tick one) Online Credit Card (we will email you the invoice with a payment link) Direct Wire Transfer (we will email you the invoice with our bank details) Authorising Signature: Option 3 - Phone Us on +44 (0)1300 321501 We will be delighted to give you our personal attention. 15